MML Investors Services
TVRD

MML Investors Services’s Tvardi Therapeutics TVRD Stock Holding History

MML Investors Services’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,266
Closed -$61K – 2577
2023
Q4 		$61K Sell
2,266
-450
-17% -$18.6K ﹤0.01% 2413
2023
Q3 		$164K Buy
2,716
+1,109
+69% +$104K ﹤0.01% 2192
2023
Q2 		$164K Buy
1,607
+404
+34% +$55.7K ﹤0.01% 2195
2023
Q1 		$213K Buy
1,203
+55
+5% +$18.4K ﹤0.01% 1880
2022
Q4 		$444K Sell
1,148
-51
-4% -$19.4K ﹤0.01% 1566
2022
Q3 		$404K Buy
1,199
+756
+171% +$274K ﹤0.01% 1535
2022
Q2 		$146K Buy
443
+83
+23% +$29.1K ﹤0.01% 1948
2022
Q1 		$157K Buy
+360
New +$148K ﹤0.01% 1995
2021
Q4 		– Sell
-652
Closed -$362K – 2074
2021
Q3 		$362K Buy
+652
New +$327K ﹤0.01% 1541

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

MML Investors Services's TVRD Position: Q1 2024 in Review

MML Investors Services sold out of Tvardi Therapeutics (TVRD) in Q1 2024, closing a stake of 2,266 shares — an estimated $61K sold.

MML Investors Services first reported a position in TVRD in Q3 2021 and held it in 9 quarters. The position peaked at $444K in Q4 2022. 97 funds tracked by Wall St. Rank hold TVRD as of Q1 2024.

  • MML Investors Services reported no remaining Tvardi Therapeutics position as of Q1 2024 after selling out during the quarter.
  • MML Investors Services sold 2,266 Tvardi Therapeutics shares in Q1 2024, an estimated $61K.
  • MML Investors Services first reported a position in Tvardi Therapeutics in Q3 2021 and held it in 9 quarters.
  • MML Investors Services's Tvardi Therapeutics position peaked at $444K in Q4 2022.
  • 97 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2024.

Based on MML Investors Services's 13F filing for Q1 2024, filed 14 May 2024.